Borviz T 2.5MG Injection

Borviz T 2.5mg Injection is a prescription based medicine used in the treatment of multiple myeloma and mantle cell lymphoma. The medicine has targeted therapy that works by blocking the growth of cancer cells. The medicine interferes with the cancer cell protein activity. It stops the multiplication of tumor cells and helps to slow down the disease progression. Its active ingredient is Bortezomib Injection IP belongs to the group of proteasome inhibitor. Its job is to break down damaged or unwanted proteins inside the cell. When it is blocked, these damaged proteins start accumulating in cancer cells, causing cancer cells to die. The medicine should only be used under doctor's prescription and supervision.

Multiple myeloma and mantle cell lymphoma

Consult the doctor if any of the side effects persist by using Borviz T 2.5mg Injection as it may cause acute as well as chronic symptoms. It is important to follow the doctor's prescription carefully and report any of these unusual symptoms immediately:
● High blood pressure
● Breathlessness
● Fungal infection
● Anemia
● Itching
● Pneumonia
● Dry skin
● Gastronintestinal bleeding
● Dehydration
● Motor neuropathy

Broviz T injection usually given in the arm or abdomen as directed by the doctor or supervision of healthcare professional. It should be taken at the fixed time everyday to enhance the effectiveness of the treatment. Do not miss or overdose the medication as it may lead to serious side effects. Regular follow ups and appointments are necessary while the treatment going on.

Multiple myeloma and mantle cell lymphoma are caused by genetic mutation in blood cells which lead to uncontrolled cell growth in the bone marrow or lymphatic system. Broviz T Injection is anti-cancer medication, directly target on the gene mutation. It works as a proteasome inhibitor, interfering with the breakdown and damaged of protein inside the cells, causing the cancer cells to die.

• Yamamoto, S., Kawashiri, T., Higuchi, H., Tsutsumi, K., Ushio, S., Kaname, T., ... & Egashira, N. (2015). Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats. Journal of pharmacological sciences, 129(1), 43-50.
• Moschetti, G., Amodeo, G., Maftei, D., Lattanzi, R., Procacci, P., Sartori, P., ... & Franchi, S. (2019). Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy. Journal of Neuroinflammation, 16(1), 89.
• Xie, J. D., Chen, S. R., Chen, H., & Pan, H. L. (2017). Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord. Neuropharmacology, 123, 477-487.
• Tung, D., Cheung, P. H., Kaur, P., Foreman, O., Kavirayani, A., Hain, H. S., & Saha, S. (2011). Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models. Pharmacology, 88(1-2), 100-113.
• Li, C., Deng, T., Shang, Z., Wang, D., & Xiao, Y. (2018). Blocking TRPA1 and TNF-α signal improves bortezomib-induced neuropathic pain. Cellular Physiology and Biochemistry, 51(5), 2098-2110.